JAK inhibitors in difficult-to-treat adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis
Authors' conclusion
JAKi agents may be a therapeutic option for some patients with difficult-to-treat Still's disease, especially those with partial response to medium- or high-dose CS or biologics.
Study context
- Population
- Patients with difficult-to-treat sJIA or adult-onset Still's disease (AOSD) with inadequate response to CS or csDMARDs or bDMARDs, French hospital departments of rheumatology, paediatric rheumatology and internal medicine7 adults
- Participants
- 9 patients
- Outcome
- Efficacy and safety of JAKi agents
Methodological detailsnational survey, multicentre, standardized questionnaire
- National survey
- Multicentre
- Standardized questionnaire
Main finding
As reported in the abstract
Response to JAKi · median follow-up 16 (1-33) months
Complete remission
2 of 9
Partial response
3 of 9
Treatment failure
4 of 9
Observational data: associations, not effects.
Further findings
CS use at last visit
- CS could be decreased but not stopped
Safety
| Outcome | Values |
|---|---|
| Severe adverse eventsTolerance acceptable | JAKi 0 events |
Original publication
JAK inhibitors in difficult-to-treat adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford). Published 3 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →